EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer

Qing-Hua Yin, Qiang Zhou, Jian-Bing Hu, Jie Weng, Er-Dong Shen, Fang Wen, Song-Lian Liu, Lei-Lan Yin, Ya-Jun Tong, Ling Long, Ke-Wei Tang, Si-Te Bai und 1 weitere

Frontiers in Pharmacology · 08.07.2025 · 16

DOI: 10.3389/fphar.2025.1605531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.07.2025. Verfasst von Qing-Hua Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yueyang Central Hospital, Yueyang, Hunan, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non-small cell lung cancer (NSCLC) remains a lethal malignancy with limited therapeutic options. Although dihydroartemisinin (DHA) exhibits anticancer properties, its mechanisms in NSCLC are incompletely understood. This study investigated the role of the miR-497-5p/SOX5 axis in mediating DHA’s effects on NSCLC.

Methods

In vitro experiments utilized A549 and H1299 cells treated with DHA (50 μM). Proliferation, migration, invasion, and apoptosis were assessed. miR-497-5p and SOX5 expression was modulated via genetic silencing. In vivo , A549 xenograft tumor growth in mice was evaluated under DHA treatment (25/50 mg/kg).

Results

DHA significantly suppressed proliferation, migration, and invasion while inducing apoptosis in vitro . Mechanistically, DHA upregulated miR-497-5p and downregulated SOX5—overexpressed in clinical NSCLC. Silencing miR-497-5p attenuated DHA’s effects and increased SOX5, whereas SOX5 knockdown reversed miR-497-5p inhibition. In vivo , DHA dose-dependently inhibited tumor growth with miR-497-5p elevation and SOX5 suppression, effects abrogated by miR-497-5p inhibition but rescued by SOX5 knockdown.

Discussion

DHA exerts antitumor activity by activating the miR-497-5p/SOX5 axis, revealing a novel mechanism. Bridging efficacious in vitro concentrations with clinically achievable dosing remains essential for therapeutic translation.

Schlagwörter

Stichwörter der Autor:innen

SOX5anticancer activitydihydroartemisinin (DHA)miR-497-5pnon-small cell lung cancer (NSCLC)

Autor:innen und Institutionen

  • Department of Oncology, Yueyang Central Hospital, Yueyang, Hunan, China.

Zitieren

APA

Yin, Q. H., Zhou, Q., Hu, J. B., Weng, J., Shen, E. D., Wen, F., Liu, S. L., Yin, L. L., Tong, Y. J., Long, L., Tang, K. W., Bai, S. T., & Ou, L. D. (2025). Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1605531

Vancouver

Yin QH, Zhou Q, Hu JB, Weng J, Shen ED, Wen F, et al. Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1605531

BibTeX
@article{Yin2025,
  author = {Yin, Qing-Hua and Zhou, Qiang and Hu, Jian-Bing and Weng, Jie and Shen, Er-Dong and Wen, Fang and Liu, Song-Lian and Yin, Lei-Lan and Tong, Ya-Jun and Long, Ling and Tang, Ke-Wei and Bai, Si-Te and Ou, Lu-Di},
  title = {Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1605531}
}
Kostenlos starten →